- A pack of gum, e.g.: “What the Proceeds of a BlackBerry Class Action Could Buy” [Rebecca Greenfield, Atlantic Wire]
- A million law firm ads later: “Pfizer’s Anti-Smoking Drug [Chantix] Isn’t Riskier Than Patches, FDA Says” [Bloomberg]
- Over 9/11 attacks: “Court Recommends al-Qaida Pay $9 Billion to Insurers” [NYLJ]
- Green alarmism over cosmetics — justified? [Dana Joel Gattuso, CEI; related here, here]
- Arpaio-Thomas follies continue in Arizona courtroom [Coyote, earlier]
- Upcoming: November 4 conference “Silenced” in D.C. on blasphemy laws and hate speech; Bruce Bawer, Nina Shea et al. [Federalist Society]
- “I dreamed I swayed the jury… in my Maidenform bra” [Retronaut, scroll]
Posts Tagged ‘pharmaceuticals’
October 17 roundup
- “Convicted King of Class Actions Builds Aviary, Regrets Nothing” [Lerach, Bloomberg profile]
- Teva/Baxter suits: Latest Nevada you-made-the-vials-too-big propofol verdict makes no more sense than first [Glenn Lammi, Forbes; Ted at PoL]
- EPA malicious prosecution in Hubert Vidrine case won’t be “isolated” unless we change our thinking [Ken at Popehat]
- Title IX coordinator training: “How federal regulations are making college ‘risk management’ lawyers rich” [Robert Shibley, Daily Caller] A lawyer spots more problems with Department of Education regulations on campus sexual assault [Robert Smith, RCP]
- Time to admit: on consequences of protecting big banks from capitalism, “Occupy” has a point [Nicole Gelinas, City Journal]
- Lawsuits accuse Boeing of engine-air-in-cabin “fume events” [MSNBC]
- About those “Topeka decriminalizes domestic violence” stories [Lowering the Bar]
Tough cookies, asthma sufferers
The federal government really is going through with its ban on over-the-counter asthma inhalers — sometimes the only ones readily available in emergencies — because of the minute CFC emissions for which they are responsible. [Mark Hemingway, Weekly Standard, Atlantic Wire; earlier]
September 19 roundup
- Educator: please don’t bring lawyers to parent-teacher meetings [Ron Clark, CNN] Steve Brill: what I found when I investigated NYC teacher “rubber rooms” [Reuters] “The Six Dumbest Things Schools Are Doing in the Name of Safety” [Cracked] School waterfall liability [Lincoln, Neb. Journal-Star]
- As predicted: “Dodd-Frank Paperwork a Bonanza for Consultants and Lawyers” [NYT]
- “Running out of common drugs” [Josh Bloom, NY Post] Pharmaceutical shortages: the role of Medicare price controls [Richard Epstein, Hoover; earlier here, here, etc.]
- DoT insists on exposing private flight plans online. Yoo-hoo, privacy advocates? [Steve Chapman]
- New class action law in Mexico includes loser-pays provision [WSJ]
- Newt Gingrich candidacy revives memories of his 1995 call for death penalty (with “mass executions”) for drug smuggling [NYT archive via Josh Barro; see also @timothy_watson “Sounds kinda like Shariah Law to me.”)
- “Cy pres slush fund in Georgia under ethics investigation” [PoL]
September 14 roundup
- Large newspaper group drops RightHaven; “it was a dumb idea” [Kravets/Wired, more] Courtroom reverses for copyright aggregator assume a comic tone [BoingBoing, Slashdot, Corporate Counsel]
- Dan Snyder drops suit against Washington City Paper [WCP, Wolfman/CL&P, Adler, earlier here, here, etc.] More reactions to TSAer’s lawsuit threat against columnist/blogger Amy Alkon [Treacher, Balko, Bader]
- Jury declines to credit testimony about when victim took Children’s Motrin [Beck]
- Mississippi high court strikes down widely noted $7 million lead paint verdict in Sherwin-Williams vs. Gaines [AP, Freeland, LNL, opinion]
- “Is suing the bar a new drunk driving trend?” [NJLRA]
- Decline of chemistry sets tells a story of fear and liability [John Browning, SETR, earlier]
- “Expectedly pleasing,” that’s me [Katherine Mangu-Ward, Reason]
September 7 roundup
- Truth through intimidation? U.K.: “Chronic fatigue syndrome researchers face death threats from militants” [Guardian] Nanotechnologists are target of Unabomber copycat [Chronicle of Higher Education]
- Blogger (and frequent Overlawyered commenter) Amy Alkon criticizes intrusive TSA agent by name, agent threatens $500K libel suit [Mike Masnick/TechDirt, Mark Bennett]
- NYT fans “pill mill” hysteria, heedless of the costs [Sullum]
- Patent litigant “pursued baseless infringement allegations in bad faith and for an improper purpose.” More loser-pays, please [NLJ, PoL]
- Great moments in link solicitation [Scott Greenfield] Quality bar at feminist lawprof blog may not be set terribly high [Popehat]
- “Wow, this photo got over 475 views from being reposted on Overlawyered” [Erik Magraken]
- “Popular Comic Strip Has Fun With Wacky Warnings” [Bob Dorigo Jones]
August 29 roundup
- Even before federal raid on Gibson, Lacey Act scared owners of vintage instruments: “I don’t go out of the country with a wooden guitar.” [Eric Felten/WSJ, AW, PoL, Trevor Burrus/Cato]
- Dear NYT contributor Bakan: getting your kids’ attention may not require overthrowing world corporate economy [Nancy French, NR “Home Front”] More: Sullum.
- “West Memphis Three” freed [Damon Root, Greenfield]
- Forest Labs case: after outcry, feds drop effort to force firing of drug company CEO not charged with wrongdoing [WSJ, WLF] Background: Charles Hooper & David Henderson, Hoover (“The FDA’s War on Drugs”), The Economist (“The government seeks to sack an innocent boss”, Diana Furchtgott-Roth, Steve McConnell/Drug and Device Law, Josh Wright/Truth on the Market]
- Google paid dearly in smartphone deal for our dysfunctional patent system [Gordon Crovitz] “Google Should Publicly Oppose Software Patents” [Timothy Lee, Forbes]
- Lawyer’s suit: Kasowitz firm ignored his “superior legal mind” [Lowering the Bar, Above the Law]
- “In Chicago, You Need a License To Help Others Get a License” [Mark Perry]
Gasp-worthy
The Food and Drug Administration has banned the only over-the-counter asthma inhaler, Primatene Mist, on the grounds that it releases chlorofluorocarbons (CFCs) and is thus bad for the ozone layer. [Chris Horner, Big Government via Alkon; Washington Post](& welcome Above the Law readers)
More from @larkinrule: “I was alone at my family cabin had an asthma attack and no inhaler. The corner store had one left. I believe it saved my life.”
“After TwIqbal, defendants don’t have to take scattershot pleading lying down”
The Supreme Court’s admirable Twombly and Iqbal precedents give a federal district court the means to turn back a shotgun lawsuit against a horde of undifferentiated defendants [McFarland v. APP Pharmaceuticals LLC, slip op., 2011 WL 2413797 (W.D. Wash. June 13, 2011) via Beck, Drug and Device Law]. Quoting the court:
[A]lleging that 93 defendants all manufactured, distributed, and/or sold all of the products that caused all of plaintiff’s injuries is not plausible. In addition, plaintiff’s allegations are internally inconsistent. The complaint alleges that “each” of the defendants manufactured the heparin that caused her injuries, but also alleges that each of the 93 defendants “separately manufactured, marketed, distributed, wholesaled, and/or sold” heparin. The inconsistencies between those allegations, which are not pled in the alternative, further highlight the implausibility of plaintiff’s allegations.
James Beck writes, “Basically, the plaintiffs in McFarland didn’t want to do even the most basic spadework of identifying the correct defendants before bringing suit, so they threw in the kitchen sink in the hope that the defendants would end up having to spend the time and effort to figure things out.” After Twombly and Iqbal, that’s become a less effective legal tactic — one of many reasons to resist the Litigation Lobby drive to get Congress to overturn the two pleading decisions.
“Too Much FDA Intervention Equals Too Few Drugs”
Bloomberg columnist Ramesh Ponnuru tackles the pharmaceutical-shortage issue covered recently in this space.
P.S. Although it is only indirectly related to the issue of manufacturing shortages, note also the interesting reader comment on the gout drug Colchicine, known and used for millennia. Per relatively recent FDA rules, colchinine and various other older drugs, formerly “grandfathered” and free for anyone to produce, have been awarded in exclusivity to a single manufacturer, at considerable cost to consumers.